Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GRN | P28799 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699062 | 0.83 | MAPK14 (0.61) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL7112019 | 0.81 | MAPK14 (0.63) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL31034603 | 0.80 | CDK8 (0.62) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL9892358 | 0.80 | CNR2 (0.59) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL1465671 | 0.80 | MAPK14 (0.62) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL19669083 | 0.79 | CDK8 (0.72) | MAPK14MAPK13MAPK12MAPK11GAA | |
| SCHEMBL13282103 | 0.78 | TSHR (0.45) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL12746805 | 0.78 | KDM4E (0.42) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL4139014 | 0.77 | CNR2 (0.56) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL1620986 | 0.77 | CNR2 (0.66) | MAPK14MAPTLMNAMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | MAPK14 1949/4885MAPT 4057/4885LMNA 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.